Compare Sunrun Inc (RUN) vs Summit Therapeutics Inc (SMMT) Price & Performance

Sunrun (RUN) trades at $9.79, down 0.81% amid bearish technical signals despite strong earnings beats. The company shows solid profitability with 11.59% net margin and attractive valuation metrics including P/E of 6.82 and P/B of 0.69. Recent Q2 2026 results beat expectations with $0.42 EPS versus $0.23 estimate, though shares declined on reduced full-year guidance and Goldman Sachs price target cut from $18 to $15.

While fundamentals remain strong with growing storage adoption and positive cash generation, near-term headwinds include guidance reductions and solar sector volatility. Analyst consensus remains bullish with $14.38 price target representing 47% upside potential, but investors face execution risks amid the company's shift toward direct sales and competitive market pressures.

Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.

Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.